#CJASN
LightNews LightNews
edgarvlermamd.medsky.network
Renal Physiology for the Clinician Series
#Nephpearls

👉 journals.lww.com/cjasn/pages/...
December 4, 2024 at 5:22 AM
jasminenephro.bsky.social
🫘Breaking barriers and gender bias in Nephrology

Interesting read in CJASN by @kidneydoc101.bsky.social

journals.lww.com/cjasn/pages/...
November 25, 2024 at 11:46 AM
haoyin.bsky.social
Glomerular Neovascularization
#DiabeticKidneyDisease #CaseReport

#SpatialTranscriptomics #Visium @10xGenomics

50-μm section multiplex IF

TEM▶️⏫Periglomerular Capillaries + de novo vascular anastomosis crossing Bowmen capsule

#KPMProject #CJASN 2024
journals.lww.com/cjasn/abstra...
February 5, 2025 at 12:49 PM
hswapnil.medsky.social
The RCT of the ETC: financial incentives and penalties to increase transplant waitlisting did….not do much

journals.lww.com/cjasn/fullte... in @asnpublications.bsky.social CJASN

It’s great that this was framed as an RCT rather than a P4P so we can stop throwing more money at this?
visual abstract of the trial from @nephroseeker.bsky.social
January 12, 2025 at 11:51 PM
hswapnil.medsky.social
I think Aliza Thompson is an unsung hero in this story for spearheading the albuminuria acceptance at FDA

journals.lww.com/cjasn/pages/...

#NephJC
journals.lww.com
November 19, 2025 at 3:00 AM
jasminenephro.bsky.social
🫘Rhabdomyolysis AKI management

journals.lww.com/cjasn/fullte...

CJASN
November 23, 2024 at 3:20 AM
rheaultm.bsky.social
New out today:

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Genetic FSGS CAN be treated. journals.lww.com/cjasn/abstra...
December 23, 2025 at 8:16 PM
garysinger.bsky.social
An opposing view would be to throw caution to the wind and implement GDMT at a more accelerated rate similar to CHF

journals.lww.com/cjasn/fullte...

@asnkidney.bsky.social #CJASN
@brendonneuen.bsky.social

#NephJC
December 18, 2024 at 2:50 AM
kidneyboy.bsky.social
#Flozins in ADPKD. Interesting VA data suggesting that they may be safe and have a role in renal preservation

journals.lww.com/cjasn/fullte...
July 17, 2025 at 7:09 PM
michael-toal.bsky.social
Excited to share our publication on international kidney biopsy practice in CJASN. Thanks @kidneyboy.bsky.social and @hswapnil.bsky.social for the support!

Generously funded by NIKRF through @qubelfastofficial.bsky.social

journals.lww.com/cjasn/fullte...
January 16, 2025 at 8:59 PM
hswapnil.medsky.social
Excellent review on …renal denervation in CJASN

journals.lww.com/cjasn/pages/...

Spot the discrepancy in the figure!

#Renal4Ever
Figure 1 KDN in legend RDN in figure
December 9, 2025 at 11:42 PM
asnpublications.bsky.social
ASN Publications is on Cloud 9 to announce that we’re now on Bluesky!

Follow us @asnpublications.bsky.social for the latest from JASN, CJASN, Kidney360, and Kidney News, and tag us in your publication posts too.

@asnkidney.bsky.social
@kdjhaveri.bsky.social
@rajmehrotra.bsky.social
January 8, 2025 at 8:25 PM
podocytetalk.bsky.social
These findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or polypharmacy.

CJASN 19(9):p 1119-1129, September 2024

#podocytetalk #Nephpearls #CKD #nephsky

journals.lww.com/cjasn/fullte...
February 2, 2025 at 3:36 PM
hswapnil.medsky.social
We need a good biomarker for IgAN given the impoartance of immunosuppression (vs non-specific therapies: RASi, Flozins, ERA)

But the Gd-IgA doesn’t seem so impressive to me?

journals.lww.com/cjasn/pages/...

#NephSky @asnpublications.bsky.social #CJASN

VA by @corinateodosiu.bsky.social
Visual abstract of the study from Corina
September 12, 2025 at 12:24 PM
brendonneuen.bsky.social
New in CJASN:

Our meta-analysis of 66 CKD trials shows both acute & chronic GFR slope independently predict clinical outcomes

Findings support 3-year total slope as the optimal surrogate endpoint for CKD trials

@asnpublications.bsky.social: doi.org/10.2215/CJN....
April 21, 2025 at 11:26 AM
hswapnil.medsky.social
When @rajmehrotra.bsky.social is giving a talk on the factors for home dialysis stagnation and growth in US at the #CSNAGM

We get to see a CJASN abstract! From Divya Bajpai
Visual Abstract
May 9, 2025 at 9:11 PM
hswapnil.medsky.social
Promising!

flozination in ADPKD (mostly older adults with DM or CVD) - presumably those with another valid indication - associated with slower GFR slope

journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social #CJASN

With no obvious harm signal
Sodium-Glucose Cotransporter-2 Inhibitor Therapy and... : Clinical Journal of the American Society of Nephrology
study within the Veterans Health Administration included adults with an ADPKD diagnosis code who initiated SGLT2i between January 2017 and May 2023. Repeated measures models were used to evaluate eGFR...
journals.lww.com
May 20, 2025 at 9:49 PM
yalenephrology.bsky.social
Check out this article by Dr. Justin Belcher & many collleagues from Yale GI showing kidney tubular secretion can distinguish ATI from other AKI causes in cirrhosis patients - a game-changer for treatment decisions! @asnpublications.bsky.social #CJASN🔬

journals.lww.com/cjasn/abstra...
journals.lww.com
September 26, 2025 at 12:57 PM
kidneyboy.bsky.social
Oh look, a list of the 30 best nephrology podcasts.

www.millionpodcasts.com/nephrology-p...
Best 30 Nephrology Podcasts
Best Nephrology Podcasts to Listen to ⋅ 1. Freely Filtered, a NephJC Podcast ⋅ 2. Kent's Kidney Stories ⋅ 3. Channel Your Enthusiasm ⋅ 4. Clinical Journal of the American Society of Nephrology (CJASN)
www.millionpodcasts.com
June 21, 2025 at 2:54 PM
brendonneuen.bsky.social
SGLT2i in CKD: impact beyond kidneys

🔻 15% all-cause hospitalizations
✅ Consistent regardless of eGFR, UACR & diabetes
🏥 ~36 fewer hospitalizations per 1000 pt-years

Large absolute gains for patients & health systems

Meta-analysis in @asnpublications.bsky.social

journals.lww.com/cjasn/pages/...
July 15, 2025 at 3:40 AM
kidneyboy.bsky.social
Obesity was an important risk factor for progression to ESKD in ADPKD for patients with eGFR > 60, but not for patients with eGFR 25-59.

journals.lww.com/cjasn/fullte...
May 7, 2025 at 1:41 PM
hswapnil.medsky.social
Spend less money - some blood numbers go up.

Is that bad?

🤷🏽‍♂️

The authors here think that is stifling innovation, in CJASN on PPS and shift from etelcalcitide to cinacalcet

@asnpublications.bsky.social journals.lww.com/cjasn/fullte...

#NephSky
Visual abstract
January 22, 2025 at 1:42 AM
asnpublications.bsky.social
Behind every strong publication is thoughtful peer review. During #PRW2026, CJASN recognizes its Top 5 reviewers of 2026: Drs. Steven Coca, Jonathan Zuckerman, Devika Nair, Ilia Beberashvili, and Gangkee Ko. Join us as we spotlight their reflections. #ASNCJASN
September 17, 2026 at 6:51 PM
brendonneuen.bsky.social
📢 New in CJASN: pooled analysis of all completed phase 2/3 RCTs in #IgAN

🔹 4 drug classes (steroids, B-cell, complement, non-immunological)
🔹 All ↓ proteinuria ≥30%
🔹 All improved GFR slope
🔹 Biggest benefit: B-cell therapies

journals.lww.com/cjasn/abstra...
September 12, 2025 at 2:24 AM
nephjc.bsky.social
The Mayo Imaging Classification (MIC) uses htTKV + age to predict decline. 1A = slow, 1E = rapid. #NephJC journals.lww.com/cjasn/fullte...
March 26, 2025 at 1:17 AM